ArticleDrug development and industrial pharmacy2009
Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.
Article in Drug development and industrial pharmacy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- The Current State of the Art in PAMAM and PLL Dendrimers, Boron Clusters, and Their Complexes for Biomedical Use.Biomedicines · 2026Review
- Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.Current drug delivery · 2026Review
- Phenothiazine-linked glutamic acid dendrons: an easy access and a new class of SARS-CoV-2 main protease inhibitors.Royal Society open science · 2025Article
- Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies.Pharmaceutics · 2022Review
- Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Antiviral Polymers: A Review.Polymers · 2022Review
- Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.Pharmaceutics · 2021Review
- Peptides and Dendrimers: How to Combat Viral and Bacterial Infections.Pharmaceutics · 2021Review
- Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells.International journal of nanomedicine · 2013Article
- Enhanced bioactivity of internally functionalized cationic dendrimers with PEG cores.Biomacromolecules · 2012Article
- Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluation.Molecular pharmaceutics · 2011Article
- Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers.International journal of pharmaceutics · 2010Article
- Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates.Biomaterials · 2010Article
- Targeting Trojan Horse leukocytes for HIV prevention.AIDS (London, England) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
SPL7013 is the sodium salt of a sulfonated dendrimer that has potent antiviral properties. VivaGel, a topical gel containing 3% (wt/wt) SPL7013, is in development as a vaginal microbicide. BufferGel is a Carbopol-based acidic buffering gel that enhances the natural protective action of the vagina to produce a broad-spectrum microbicidal environment. The positive attributes of both gels were combined into a combination vaginal microbicidal gel having dual mechanisms of action. A 3% (wt/wt) SPL7013 combination gel, pH 3.7, was developed and fully characterized and was shown to have more than twofold greater acidic buffering capacity than BufferGel. Ultracentrifugation experiments demonstrated that SPL7013 was not sequestered or entropically trapped in the viscous gel, thereby confirming, along with viral challenge studies, that SPL7013 has sufficient mobility in the viscous gel to exert antiviral properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.